The gap is closing
Historically, surgery was the only option producing dramatic weight loss (25%+). Medications managed 5–10% at best. The introduction of GLP-1 medications has fundamentally changed this equation. Mounjaro's ~21% average weight loss — with some patients losing 30%+ — is approaching surgical territory. For many patients, medication now provides "good enough" results without the risks, recovery, and permanence of surgery.
When to consider medication first
- BMI 27–40 — you haven't tried prescription medication yet
- You prefer to start with the least invasive option
- You're not a surgical candidate due to other health conditions
- You want a reversible treatment
- You have a fear of surgery or anaesthesia
When to consider surgery
- BMI ≥40 or BMI ≥35 with serious comorbidities
- You've tried GLP-1 medications without sufficient results
- You need the maximum possible weight loss for health reasons
- Long-term medication cost is unsustainable and you can access public surgery
- You're ready for a permanent structural change
The combined approach
Many bariatric surgeons now prescribe GLP-1 medications before surgery (to reduce surgical risk by losing some weight first), after surgery (to prevent weight regain), or as an alternative for patients who don't qualify for or want surgery. The two approaches are increasingly complementary rather than competing.
Cost comparison over 5 years
| Medication (Wegovy) | Surgery (private sleeve) | |
|---|---|---|
| Year 1 | $4,500 | $20,000 |
| Year 2 | $5,500 | $500 |
| Year 3 | $5,500 | $500 |
| Year 4 | $5,500 | $500 |
| Year 5 | $5,500 | $500 |
| 5-year total | $26,500 | $22,000 |
Surgery is cheaper over 5+ years if you pay privately. If you access public surgery (free but long waitlist), it's dramatically cheaper. However, if Wegovy gets PBS listed ($380/year), medication becomes far cheaper than surgery at any timeframe.